Lyra Therapeutics Profit Margin

Lyra Therapeutics (LYRA) currently reports a profit margin of -7266.08% as of December 2025. That compares with -6090.94% in the prior-year period — down 19.3% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Lyra Therapeutics's profit margin history and peer comparisons.

Lyra Therapeutics's profit margin decreased from -6090.94% to -7266.08% — a 19.3% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lyra Therapeutics's profit margin of -7266.08% is lower than the Healthcare sector average of 21.34%. That is roughly 34156.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Lyra Therapeutics's current -7266.08% should be judged against Healthcare norms (sector average: 21.34%) and against LYRA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -7266.08%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Lyra Therapeutics, and consider following LYRA for alerts when major investors trade the stock.